Synergistic growth inhibition of cancer cells harboring the RET/PTC1 oncogene by staurosporine and rotenone involves enhanced cell death
Synergistic growth inhibition of cancer cells harboring the RET/PTC1 oncogene by staurosporine and rotenone involves enhanced cell death
复制标题
DOI：
10.1007/s12038-011-9100-7
复制
发表时间：
2011-09-01
影响因子：
2.9
通讯作者：
Soares, Paula
中科院分区：
文献类型：
--
作者：
Goncalves, Antonio Pedro;Videira, Arnaldo;Soares, Paula
TPC-1是一种高增殖的甲状腺乳头状癌细胞系。这些细胞表达RET/PTC1融合蛋白，其异构体在本工作中得到了表征。细菌生物碱星状孢子素和植物提取物鱼藤酮是一种对TPC-1细胞生长具有抑制协同作用的致死药物。我们表明，这种协同作用伴随着细胞死亡诱导的增强。星状孢子素单独诱导细胞周期停滞于G(1)期，而鱼藤酮诱导细胞停滞于G(2)/M期。我们推测，这种附加压力可能促使细胞死亡，导致药物组合的协同作用。这些数据强调了星形孢菌素和鱼藤酮联合作为抗癌工具的潜在用途。
TPC-1 is a highly proliferative thyroid papillary carcinoma-derived cell line. These cells express the RET/PTC1 fusion protein, whose isoforms are characterized in this work. The bacterial alkaloid staurosporine and the plant extract rotenone are death-inducing drugs that have an inhibitory synergistic effect on the growth of TPC-1 cells. We show that this synergism is accompanied by an enhancement of the induction of cell death. Staurosporine alone induces cell cycle arrest in G(1), whereas rotenone induces arrest in G(2)/M. We suggest that this additive pressure may drive cells to die, resulting in the synergistic interaction of the drug combination. These data emphasize the potential use of the staurosporine plus rotenone combination as an anticancer tool.